[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-434322-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-434322-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","efficacy-and-safety-of-oral-vinorelbine-with-concurrent-radiotherapy-in-unresectable-stage-iii-non-small-cell-lung-cancer-following-neoadjuvant-chemoimmunotherapy-a-single-arm-phase-2-trial","Efficacy and safety of oral vinorelbine with concurrent radiotherapy in unresectable stage III non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a single-arm, phase 2 trial","","A single-arm phase 2 trial evaluated whether oral vinorelbine plus concurrent thoracic radiotherapy can provide effective and tolerable treatment for unresectable stage III non-small cell lung cancer after neoadjuvant chemoimmunotherapy in patients unsuitable for concurrent intravenous chemotherapy. Forty-six participants received weekly oral vinorelbine with concurrent RT, assessing objective response rate as the primary endpoint and disease control, safety, overall survival, and progression-free survival as secondary endpoints. Results showed an ORR of 52.1% and a 95.7% disease control rate, with predominantly grade 1–2 adverse events and no grade 3–4 treatment-related events recorded.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-and-safety-of-oral-vinorelbine-with-concurrent-radiotherapy-in-unresectable-stage-iii-non-small-cell-lung-cancer-following-neoadjuvant-chemoimmunotherapy-a-single-arm-phase-2-trial/434322/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-oral-vinorelbine-with-concurrent-radiotherapy-in-unresectable-stage-iii-non-small-cell-lung-cancer-following-neoadjuvant-chemoimmunotherapy-a-single-arm-phase-2-trial/434322.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Who were the participants in this study?","Question",{"text":63,"@type":64},"The trial enrolled 46 individuals with unresectable stage III non-small cell lung cancer who received neoadjuvant chemoimmunotherapy and were not candidates for concurrent intravenous chemotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was the primary endpoint?",{"text":68,"@type":64},"The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate, safety, overall survival, and progression-free survival.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key efficacy and survival findings?",{"text":72,"@type":64},"ORR was 52.1% and disease control rate was 95.7%. Median follow-up was 22.5 months; median PFS was 18.0 months and median OS was not reached.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},434322,1790791086,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":106,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of the National Cancer Center 5 (2025) 593–599  \nContents lists available at ScienceDirect  \nJournal of the National Cancer Center  \njournal [homepage:](homepage: www.elsevier.com/locate/jncc)[ www.elsevier.com/locate/jncc](homepage: www.elsevier.com/locate/jncc)  \n| Short Communication |  |  |  |\n| --- | --- | --- | --- |\n| Efficacy and safety of oral vinorelbine with concurrent radiotherapy in unresectable stage III non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a single-arm, phase 2 trial |  |  | |\n| Xinrong Lian†, Gulidanna Shayan†, Shijie Yang, Wenyang Liu, Tao Zhang, Jima Lv,\u003Cbr>Wenqing Wang, Jianyang Wang, Xin Wang, Zefen Xiao, Zongmei Zhou, Nan Bi∗, Lei Deng∗\u003Cbr>Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China |  |  |  |\n| a r t i c l e i n f o |  | a b s t r a c t |  |\n| Keywords:\u003Cbr>Oral vinorelbine\u003Cbr>Concurrent chemoradiotherapy Neoadjuvant chemoimmunotherapy Stage III non–small cell lung cancer Clinical trial |  | Background: Individuals with unresectable stage Ⅲ non-small cell lung cancer (NSCLC) who receive complete concurrent chemoradiotherapy (cCRT) can benefit from long-term survival. Although neoadjuvant chemoimmunotherapy (NACIT) have achieved breakthroughs in treating unresectable stage Ⅲ NSCLC, patients who have received induction chemoimmunotherapy are considered poor candidates for cCRT due to concerns about tolerability. Oral vinorelbine chemotherapy is widely used in clinical settings because of its safety, even for frail patients. The objective of this trial was to assess the efficacy and safety of oral vinorelbine plus concurrent radiotherapy (RT) for individuals with unresectable stage Ⅲ NSCLC following NACIT who were not candidates for concurrent intravenous chemotherapy.\u003Cbr>Methods: This was a single-arm, phase 2 trial. The primary endpoint was the objective response rate (ORR), while the secondary endpoints consisted of the disease control rate (DCR), safety, overall survival (OS), as well as progression-free survival (PFS).\u003Cbr>Results: Between March 10, 2023 and April 24, 2025, 46 individuals with unresectable stage Ⅲ NSCLC were administered oral vinorelbine plus thoracic RT. Patients were treated with oral vinorelbine (60 mg/m2 once a week for 2 weeks as induction therapy before thoracic RT) and 30 mg/m2 per week with concurrent RT (59.4– 60.2 Gy) over 5.5 weeks. The median age of the patients was 62.5 years, with 42 being male (91.3 %). The ORR was 52.1 %(95 % confidence interval [CI], 35.1 %–65.9 %), with 24 partial responders. A 95.7 % DCR (85.5 %–98.8 %) was observed, and 20 patients had stable disease. The median follow-up was 22.5 months; the median PFS was 18.0 months and the median OS was not reached. The most commonly observed adverse events (AEs) included leukopenia (grade 1, 26.1 %), anemia (grade 1, 17.4 %), neutropenia (grade 1, 10.9 %), acute esophagitis (grade 2, 17.4 %), and treatment-related pneumonitis (grade 1–2, 60.9 %). No grade 3 or 4 treatment-related AEs were recorded.\u003Cbr>Conclusion: In individuals with unresectable stage Ⅲ NSCLC who had received NACIT and were not candidates for concurrent intravenous chemotherapy with RT, the oral vinorelbine plus concurrent RT demonstrated promising antitumor efficacy with acceptable toxicity profiles.\u003Cbr>Trial registration: [ClinicalTrials.gov](ClinicalTrials.gov) (NCT06540950). |  |\n\n1. Introduction  \nNeoadjuvant chemotherapy together with immunotherapy has obviously improved the clinical outcomes of individuals suffering from non-small cell lung cancer (NSCLC).1 , 2 In potentially resectable stage Ⅲ NSCLC, ongoing phase 3 clinical trials suggest that neoadjuvant  \nchemoimmunotherapy (NACIT) with platinum-containing chemotherapy might be the preferred neoadjuvant treatment.2 , 3 For patients with newly diagnosed unresectable stage Ⅲ NSCLC, tumors are usually t","cbCaihZeiKAHr7bk","https://ap.wps.com/l/cbCaihZeiKAHr7bk","pdf",1040733,"English","# Abstract\n## Introduction\n## Trial design and methods\n## Results\n## Conclusion","[{\"question\":\"Who were the participants in this study?\",\"answer\":\"The trial enrolled 46 individuals with unresectable stage III non-small cell lung cancer who received neoadjuvant chemoimmunotherapy and were not candidates for concurrent intravenous chemotherapy.\"},{\"question\":\"What was the primary endpoint?\",\"answer\":\"The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate, safety, overall survival, and progression-free survival.\"},{\"question\":\"What were the key efficacy and survival findings?\",\"answer\":\"ORR was 52.1% and disease control rate was 95.7%. Median follow-up was 22.5 months; median PFS was 18.0 months and median OS was not reached.\"}]","Efficacy and safety of oral vinorelbine with concurrent radiotherapy in unresectable stage III non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a single-arm, phase 2 trial | PDF",1790668573,18]